KEYNOTE SPEAKERS

---

Fiona WOOD

University of Western Australia

The evolution and challenges introducing cell based therapies into burn care and scar therapy

Home Page

Bruce LEVINE

The University of Pennsylvania

Genetically engineered immunity for cancer: the development and global regulatory approvals of chimeric antigen receptor (CAR) T cells and what’s coming next

Home Page

---

INVITED SPEAKERS

Firdaus Abdul Aziz

University of Malaya

Expedited regulatory pathways for stem cell-based products in Malaysia: ethical and legal considerations

Home Page

Antonio Bertoletti

Duke-NUS Medical School

T cell therapy as a localized modulator of tumor immune environment

Home Page

Christine Cheung

Nanyang Technological University Singapore

Endothelial instability predisposes ischemic stroke patients to recurrent vascular events

Home Page

---

Bryan Choi

ATEMS

Development of an injectable cartilage gel using chondrogenic progenitor cells

Home Page

John Connolly

Institute of Molecular and Cell Biology

Virus specific T cells as platform for solid tumor immunotherapy

Home Page

Justin Cooper-White

CSIRO

Softer, faster, better! – Substrate mechanics drives superior somatic cell reprogramming outcomes

Home Page

---

Anthony Davis

Dark Horse Consulting

Effective & cost-effective, but unaffordable? The future of cell and gene therapy

Home Page

Alicia Henn

Biospherix

The patient in the incubator: the cytocentric approach to avoiding suboptimal transients

Home Page

Akitsu Hotta

Kyoto University

Minimizing immunogenicity of iPS cells by custom disruption of HLA genes utilizing CRISPR-Cas9 genome editing: towards 2nd generation iPS cell stock for cost-effective cell therapy

Home Page

---

Ohad Karnieli

ADVA Biotechnology

Bringing immune cell therapies to patients, innovative solutions for CAR T manufacturing, enabling scalability and cost reduction

Home Page

Shin Kawamata

Foundation for Biomedical Research and Innovation

In process monitoring for mass production of pluripotent stem cells

Home Page

Mickey Koh

St George's Hospital

Making the unproven proven

Home Page

---

Antonio Lee

MEDIPOST Co., Ltd

Commercialization of advanced allogeneic cell therapy product in Korea and beyond

Home Page

Mayasari Lim

RoosterBio Inc.

Radically simplifying scale-up and clinical translation of hMSCs and extracellular vesicles

Home Page

Xiangliang Lin

ESCO Aster

Continuous bioprocessing platform for Car T

Home Page

---

Wendy Lipworth

University of Sydney

The oversight of clinical innovation in a medical marketplace

Home Page

Michael Lotze

University of Pittsburgh

Expansion of human tumor infiltrating γδ T cells for cancer therapy

Home Page

Maksim Mamonkin

Baylor College of Medicine

Engineering off-the-shelf therapeutic T-cells to resist host immune rejection

Home Page

---

Charlotte Morgan

Regeneus Ltd

Regeneus’ novel allogeneic stem cell platform for Osteoarthritis

Home Page

May Win Naing

SIMTech

Automated cell expansion: Trends & outlook of critical technologies

Home Page

Lee Lee Ong

Health sciences authority

Regulatory updates on cell and gene therapy products in Singapore

Home Page

---

Jaichandran Sivalingam

Bioprocessing Technology Institute

Future of transfusion medicine – Human induced pluripotent stem cells derived blood?

Home Page

Arthur Sampaio

Stemcell technologies

Characterization of extracellular vesicles produced by human mesenchymal stromal cells in an improved extracellular vesicle-free medium

Home Page

Cameron Stewart

University of Sydney

The use of professional disciplinary systems to regulate innovation: lessons from stem cell practice in Australia

Home Page

---

Satoshi Takahashi

University of Tokyo

Stem cell expansion of cord blood graft” vs “bridging support with 3rd party hematopoietic stem/progenitor cells

Home Page

Lip Kun Tan

National University Hospital

Establishing the National Cell Therapy Program for process development and clinical manufacturing of cell & gene therapy products in Singapore

Home Page

Drew Titmarsh

Scaled Biolabs Inc

Closing the loop: a software hypervisor to direct a structured, data science approach to cell process development

Home Page

---

Monica Tjin

Duke-NUS

Cellular therapy for burns/skin injuries: Laminin-based epidermal keratinocytes culture system in xeno-free and chemically defined condition

Home Page

Andre van Wijnen

Mayo Clinic

The Science of stem cell therapy – parameters affecting dosing and efficacy

Home Page

Wen Bo Wang

Fate Therapeutics

Developing allogeneic cellular immunotherapies with iPSC technology

Home Page

---

Francis Wong

Singhealth

Long term clinical outcomes of stem cell therapy in cartilage repair: Are we ready for the next step?

Home Page

Lynn Yap

Duke-NUS

Cardiovascular progenitors for heart regeneration in preclinical models

Home Page

---

Jointly Organized by:
​